{"url_path":"/sec/femy/8-k/2026-06-04/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1339005/0001140361-26-023955-index.html","accession_number":"0001140361-26-023955","cik":"0001339005","ticker":"FEMY","issuer_name":"FEMASYS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1339005/0001140361-26-023955-index.html","primary_entity_key":"0001339005","primary_entity_name":"FEMASYS INC"},"word_count":628,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure.\n\nOn June 4, 2026, Femasys Inc. (the “Company”) announced that it will effect a 1-for-20 reverse stock split of its common stock, par value $0.001 per share\n(the “Common Stock”), that will become effective at 4:30 p.m. Eastern Time on June 5, 2026. The Common Stock will begin trading on a split-adjusted basis with the open of the market on June 8, 2026. The Common Stock will continue to trade under the\nexisting trading symbol “FEMY.” The new CUSIP number for the Common Stock following the reverse stock split is 31447E 204.\n\nAs a result of the reverse stock split, each 20 pre-split shares of Common Stock outstanding will be automatically combined and converted into one issued\nand outstanding share of Common Stock. No fractional shares of Common Stock will be issued in connection with the reverse stock split. Instead, fractional shares will be rounded up to the next whole share at the Depository Trust Company (DTC)\nparticipant level.\n\nStockholders of record will receive information regarding their share ownership following the reverse stock split from the Company’s transfer agent,\nBroadridge Investor Communication Solutions, Inc. Broadridge can be reached at (844) 998-0339 or by email at shareholder@broadridge.com.\n\nThe information furnished in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of\n1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as may be expressly set forth by specific reference in\nsuch filing.\n\nForward-Looking Statements\n\nThis Current Report on Form 8-K contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can\nbe identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not\nall forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and\ncould cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ\ninclude, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; our ability to develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our\nclinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product\ncandidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business,\nincluding our implementation thereof; and those other risks and uncertainties described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and other reports as filed with the Securities and\nExchange Commission. Forward-looking statements contained in this Current Report on Form 8-K are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the\nundersigned hereunto duly authorized.\n\nFemasys Inc.\n\nBy:\n\n/s/ Kathy Lee-Sepsick\n\nName: Kathy Lee-Sepsick\n\nTitle: Chief Executive Officer\n\nDate: June 4, 2026"}